Ashkan Emadi, MD, PhD, discussed the scientific rationale for this venetoclax plus pegcrisantaspase and preclinical data that supported the phase 1 study; detailed the findings from the phase 1 trial; and explained the potential role for this regimen in the management of acute myeloid leukemia.